Personalized Medicine Coalition Announces Two New Board Members
Washington, DC - November 17, 2008 — The Personalized Medicine Coalition (PMC) today announced the appointment of Jeffrey Cossman, M.D., chief scientific officer of the Critical Path Institute (C-Path), and Felix W. Frueh, Ph.D., vice president of research and development for personalized medicine at Medco Health Solutions (NYSE:MHS), to its Board of Directors.
The PMC, an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine, was launched in 2004 by more than 15 leading pharmaceutical, biotechnology, diagnostics, and information technology companies, as well as major academic centers and governmental agencies, and now includes over 150 members representing all the stakeholders with an interest in personalized medicine.
"Jeff Cossman is a pioneer in the science of personalized medicine. Felix Frueh has led the effort to incorporate personalized medicine into existing health and science policy inside the government," said Wayne Rosenkrans, PMC's president and chairman. "Their combined expertise will greatly enhance our efforts to encourage the government to become a more effective supporter of personalized medicine."
Dr. Cossman has been on the cutting edge of research in the field of personalized medicine for the last two decades. He helped found the field of molecular diagnostics, which has grown to become a major tool in personalized medicine, while at the National Cancer Institute and at Georgetown University Medical Center, where he served as Chairman of the Department of Pathology. Prior to joining C-Path, he was vice president of GeneLogic Inc., where he directed scientific and academic collaborations using microarray gene expression. At the Critical Path Institute, he is heading scientific programs which partner with the U.S. Food and Drug Administration and industry consortia that aim to speed the process for the development of new drugs and diagnostic tests.
"This emerging field of personalized medicine, built on the science of the last 10 or 20 years, carries such great promise," Dr. Cossman said. "Through teamwork across industry, academia, government, and payers, we can fulfill this promise and bring the right treatment to the right patient. The PMC complements the mission of the Critical Path Institute in fostering personalized medicine that grows from improvements in the process of developing medical products."
Dr. Frueh spent four years as associate director for genomics at the FDA, where he led the core genomics review team at the Center for Drug Evaluation and Research, and chaired the first FDA-wide pharmacogenomics review group. Prior to that work, he founded the consulting firm Stepoutside Consulting, which provided services to European biotechnology companies interested in establishing a presence in the United States. He has held senior positions at several private laboratories, and served on the faculty in the pharmacology and medical departments at Georgetown University.
Someday, genetics will be as common a factor as family history in making treatment decisions, Dr. Frueh said, but only if "technology and its use are promoted appropriately, if stakeholders come and work together, and if ways are found to protect individuals from the misuse of information needed to make such decisions. The PMC is the most important organization at the interface of science, business and policy, connecting stakeholders, communicating and debating critical policy decisions, and providing a channel to the legislative activities in Washington, D.C.-an activity of growing importance."
Elizabeth Schwinn (email@example.com)
Personalized Medicine Coalition
Critical Path Institute:
Raymond L. Woosley, president and CEO
Ann Smith, Senior Director, Public Affairs
About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information on the Personalized Medicine Coalition, please visit www.PersonalizedMedicineCoalition.org.
About the Critical Path Institute
Headquartered in Tucson, Arizona, with offices in Rockville, Maryland, the Critical Path Institute was established in 2005 as a publicly funded, nonprofit research and education institute to enable collaborations between scientists from the FDA, industry and academia. The Critical Path Institute's mission is to help implement the FDA's Critical Path Initiative by developing faster, safer and smarter pathways to new medical products. Visit www.C-Path.org for more information.
Medco Health Solutions, Inc. (NYSE: MHS) is the nation’s largest pharmacy benefit manager based on its 2007 total net revenues of more than $44-billion. Medco’s prescription drug benefit programs, covering one in five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program. Medco, the world’s most advanced pharmacyTM, is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers®; its diabetes pharmacy care practice, Liberty Medical; and its specialty pharmacy operation, Accredo Health Group. Medco is the highest-ranked independent pharmacy benefit manager on the 2007 Fortune 500 list. On the Net: www.medcohealth.com.